readthroughSign in
CompanyBRVENasdaqSan Francisco, CA

Braveheart Bio, Inc.

Braveheart Bio develops BHB-1893, an oral small-molecule cardiac myosin inhibitor for obstructive and non-obstructive hypertrophic cardiomyopathy.

SCHEDULE 13GNov 16Latest SEC filing
Nov 10Latest story